STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

STAT News

The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

관련 뉴스

1건 · 1개 매체

중도 성향 100%

1개 매체

FDA Scientists Raise Questions About Duchenne Drug

MedPage Today

중도 성향

관련 뉴스 제보는 로그인 후 가능합니다.

'science' 카테고리 뉴스

STAT의 다른 기사

Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn

STAT News

STAT+: Bracing for another Fauci hearing

STAT News

STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials

STAT News

STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more

이 뉴스, 어떠셨어요?

관련 뉴스

FDA Scientists Raise Questions About Duchenne Drug

'science' 카테고리 뉴스

DNA studies uncover a forgotten population at the top of the world

Researchers detect potentially harmful substance in solid waste

GLP-1 drugs may hold few benefits beyond physical health, study finds

STAT의 다른 기사

Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn

STAT+: Bracing for another Fauci hearing

STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials